Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus

Immunol Med. 2022 Dec;45(4):180-185. doi: 10.1080/25785826.2022.2060168. Epub 2022 Apr 6.


Anti-histone antibodies (AHAs) make their appearance in a number of systemic autoimmune diseases including systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus (DILE). Although being known for over 50 years, they are poorly studied and understood. There is emerging evidence for their use in predicting clinical features of SLE, diversifying their clinical use. AHAs, however, are probably less prevalent in DILE than once thought owing to a move away from older DILE drugs to modern biological agents which do not appear to elicit AHAs. This review examines the historical studies that have defined AHAs and looks at some of the recent work with these autoantibodies.

Keywords: Anti-histone antibodies; autoantibodies; drug-induced lupus; histone; systemic lupus erythematosus.

Publication types

  • Review

MeSH terms

  • Antibodies, Antinuclear* / adverse effects
  • Autoantibodies
  • Humans
  • Lupus Erythematosus, Systemic* / chemically induced
  • Lupus Erythematosus, Systemic* / drug therapy


  • Antibodies, Antinuclear
  • Autoantibodies